Summary
Gilead Sciences, Inc. (GILD) reported its first quarter 2011 financial results, demonstrating continued revenue growth driven by its core antiviral products, Atripla and Truvada. While product sales increased by 4% year-over-year, the company experienced a significant 80% decline in royalty revenues, primarily due to reduced Tamiflu sales. This impact on royalties, despite strong product sales, led to a decrease in net income and diluted earnings per share compared to the prior year's quarter. The company made strategic acquisitions, notably Calistoga Pharmaceuticals, to bolster its pipeline in oncology and inflammation, and also announced a new research collaboration with Yale School of Medicine. Operationally, Gilead strengthened its balance sheet through the issuance of $1 billion in senior unsecured notes and continued its aggressive share repurchase program. Despite a challenging revenue mix shift due to lower royalty income, the company maintains a strong liquidity position and a robust cash flow from operations. Investors should note the ongoing patent litigation concerning key products and the potential impact of healthcare reforms and European austerity measures on future sales and profitability.
Financial Highlights
50 data points| Revenue | $1.93B |
| Cost of Revenue | $474.11M |
| Gross Profit | $1.39B |
| SG&A Expenses | $295.57M |
| Operating Expenses | $1.02B |
| Operating Income | $901.97M |
| Interest Expense | $41.22M |
| Net Income | $651.14M |
| EPS (Basic) | $0.41 |
| EPS (Diluted) | $0.40 |
| Shares Outstanding (Basic) | 1.59B |
| Shares Outstanding (Diluted) | 1.62B |
Key Highlights
- 1Product sales increased by 4% to $1.86 billion, driven by Atripla (+7%) and Truvada (+2%).
- 2Royalty revenues saw a significant decrease of 80% to $58.7 million, primarily due to lower Tamiflu royalties.
- 3Net income attributable to Gilead decreased to $651.1 million ($0.80/share diluted) from $854.9 million ($0.92/share diluted) in the prior year quarter.
- 4The company acquired Arresto Biosciences, Inc. for $225 million plus potential future payments, strengthening its pipeline in fibrotic diseases and cancer.
- 5Gilead issued $1 billion in 4.50% senior unsecured notes due 2021.
- 6Stock repurchase activity remained strong, with $548.5 million repurchased during the quarter, and two new $5 billion repurchase programs were authorized.
- 7Cash, cash equivalents, and marketable securities increased by $1.04 billion to $6.36 billion.